AC-264613 is primarily researched for its potential therapeutic applications in the field of neuroscience and mental health. It acts as a selective agonist for the CB2 cannabinoid receptor, which is involved in modulating immune responses and inflammation. This makes it a promising candidate for treating neuroinflammatory conditions and neurodegenerative diseases such as Alzheimer's and Parkinson's. Additionally, its interaction with the CB2 receptor suggests potential benefits in managing pain and reducing inflammation without the psychoactive effects associated with CB1 receptor activation. Research is ongoing to explore its efficacy in these areas and its potential use in developing novel treatments for chronic pain and inflammatory disorders.